Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of January 2023, with the specific filing date of January 4, 2023. Enlivex Therapeutics Ltd., an Israeli company, filed this report to disclose a significant regulatory development regarding its clinical trial for Allocetra®.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes and Regulatory Developments
The primary material event is the clearance of an amended Phase II trial protocol for Allocetra® in patients with sepsis by two regulatory bodies:
- French Agency for Food, Environmental and Occupational Health and Safety.
- Belgian Federal Agency for Medicines and Health Products.
The amended protocol enables two key changes:
- Use of a frozen Allocetra® formulation for newly recruited patients.
- Expansion of the target population beyond pneumonia-associated sepsis to include patients with sepsis stemming from biliary, urinary tract, or abdominal infections.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the context of the clinical trial progress. The document serves solely to announce the regulatory approval of the protocol amendment.
Key Facts for Investor Verification
- Confirm the specific timeline for the initiation of patient recruitment under the new frozen formulation protocol.
- Verify the total number of patients targeted in the expanded study population.
- Monitor subsequent filings for any updates on trial enrollment rates or interim data results.
- Review the full text of the press release (Exhibit 99.1) for detailed scientific rationale regarding the expanded infection types.